Abstract：
Nanomedicine research has advanced dramatically in recent decades. Nonetheless, traditional nanomedicine faces significant obstacles such as the low concentration of the drug at target sites and accelerated removal of the drug from blood circulation. Various techniques of nanotechnology, including cell membrane coating, have been developed to address these challenges and to improve targeted distribution and redcue cell membrane-mediated immunogenicity. Recently, stem cell (SC) membranes, owing to their immunosuppressive and regenerative properties, have grabbed attention as attractive therapeutic carriers for targeting specific tissues or organs. Bioengineering strategies that combine synthetic nanoparticles (NPs) with SC membranes, because of their homing potential and tumor tropism, have recently received a lot of publicity. Several laboratory experiments and clinical trials have indicated that the benefits of SC-based technologies are mostly related to the effects of SC-derived exosomes (SC-Exos). Exosomes are known as nano-sized extracellular vehicles (EVs) that deliver particular bioactive molecules for cell-to-cell communication. In this regard, SC-derived exosome membranes have recently been employed to improve the therapeutic capability of engineered drug delivery vehicles. Most recently, for further enhancing NPs\' functionality, a new coating approach has been offered that combines membranes from two separate cells. These hybrid membrane delivery vehicles have paved the way for the development of biocompatible, high-efficiency, biomimetic NPs with varying hybrid capabilities that can overcome the drawbacks of present NP-based treatment techniques. This review explores stem cell membranes, SC-Exos, and hybrid SC-camouflaged NPs preparation methods and their importance in cancer therapy.
摘要：
近几十年来，纳米医学研究取得了巨大进展。尽管如此，传统的纳米药物面临着重大的障碍，例如药物在靶位的浓度低和药物从血液循环中的加速清除。纳米技术的各种技术，包括细胞膜涂层，已经开发出解决这些挑战并改善靶向分布和redcue细胞膜介导的免疫原性。最近,干细胞（SC）膜，由于它们的免疫抑制和再生特性，作为靶向特定组织或器官的有吸引力的治疗载体引起了人们的注意。将合成纳米粒子（NPs）与SC膜相结合的生物工程策略，因为它们的归巢潜力和肿瘤嗜性，最近收到了很多宣传。一些实验室实验和临床试验表明，基于SC的技术的好处主要与SC衍生的外泌体（SC-Exos）的作用有关。外泌体被称为纳米大小的细胞外载体(EV),其递送用于细胞与细胞通信的特定生物活性分子。在这方面,SC衍生的外泌体膜最近已被用于改善工程化药物递送载体的治疗能力。最近,为了进一步增强NP的功能，提供了一种新的涂层方法，该方法结合了两个独立细胞的膜。这些混合膜递送载体为生物相容性的发展铺平了道路，高效率,具有不同混合能力的仿生NP，可以克服当前基于NP的治疗技术的缺点。这篇综述探讨了干细胞膜，SC-Exos,和混合SC伪装NP的制备方法及其在癌症治疗中的重要性。
